

Michael F Mcentee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3169385/publications.pdf>

Version: 2024-02-01

38
papers

2,007
citations

279798

23
h-index

361022

35
g-index

39
all docs

39
docs citations

39
times ranked

2289
citing authors

#	ARTICLE	IF	CITATIONS
1	Erythema multiforme associated with zonisamide in a dog. <i>Veterinary Dermatology</i> , 2015, 26, 391.	1.2	14
2	Azoxymethane-Induced Colon Carcinogenesis in Mice Occurs Independently of De Novo Thymidylate Synthesis Capacity. <i>Journal of Nutrition</i> , 2014, 144, 419-424.	2.9	6
3	Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 68.	3.7	18
4	Intra-articular enzyme replacement therapy with rhDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I. <i>Molecular Genetics and Metabolism</i> , 2014, 112, 286-293.	1.1	13
5	The Involvement of Endoplasmic Reticulum Stress in the Suppression of Colorectal Tumorigenesis by Tolfenamic Acid. <i>Cancer Prevention Research</i> , 2013, 6, 1337-1347.	1.5	21
6	Zyflamend, a Combination of Herbal Extracts, Attenuates Tumor Growth in Murine Xenograft Models of Prostate Cancer. <i>Nutrition and Cancer</i> , 2012, 64, 749-760.	2.0	28
7	Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. <i>Apmis</i> , 2011, 119, 513-521.	2.0	15
8	Arterial pathology in canine mucopolysaccharidosis-I and response to therapy. <i>Laboratory Investigation</i> , 2011, 91, 665-674.	3.7	18
9	Ocular Lesions in Canine Mucopolysaccharidosis I and Response to Enzyme Replacement Therapy. , 2011, 52, 5130.		19
10	<i>Shmt1</i> Heterozygosity Impairs Folate-Dependent Thymidylate Synthesis Capacity and Modifies Risk of <i>Apcmin</i> -Mediated Intestinal Cancer Risk. <i>Cancer Research</i> , 2011, 71, 2098-2107.	0.9	50
11	<i>Mthfd1</i> is a modifier of chemically induced intestinal carcinogenesis. <i>Carcinogenesis</i> , 2011, 32, 427-433.	2.8	24
12	Zyflamend Reduces the Expression of Androgen Receptor in a Model of Castrate-Resistant Prostate Cancer. <i>Nutrition and Cancer</i> , 2011, 63, 1287-1296.	2.0	22
13	MCC-555-induced NAG-1 expression is mediated in part by KLF4. <i>European Journal of Pharmacology</i> , 2010, 637, 30-37.	3.5	14
14	Replacing the Enzyme α -L-iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type I. <i>Science Translational Medicine</i> , 2010, 2, 60ra89.	12.4	72
15	Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. <i>Molecular Genetics and Metabolism</i> , 2010, 101, 115-122.	1.1	50
16	A Green Tea Component Suppresses Posttranslational Expression of Basic Fibroblast Growth Factor in Colorectal Cancer. <i>Gastroenterology</i> , 2008, 134, 1972-1980.	1.3	62
17	Dietary n-3 Polyunsaturated Fatty Acids Enhance Hormone Ablation Therapy in Androgen-Dependent Prostate Cancer. <i>American Journal of Pathology</i> , 2008, 173, 229-241.	3.8	50
18	Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in <i>ApcMin</i> + mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2779-2787.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. <i>Journal of Clinical Investigation</i> , 2008, 118, 2868-76.	8.2	95
20	Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. <i>Molecular Genetics and Metabolism</i> , 2007, 91, 61-68.	1.1	155
21	Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Over Expression in Transgenic Mice Suppresses Intestinal Neoplasia. <i>Gastroenterology</i> , 2006, 131, 1553-1560.	1.3	156
22	Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. <i>Journal of Endocrinology</i> , 2006, 191, 437-446.	2.6	86
23	Dietary polyunsaturated fatty acids modify the progression of prostate cancer. <i>FASEB Journal</i> , 2006, 20, A993.	0.5	0
24	Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1551-1558.	4.1	42
25	Dietary Polyunsaturated Fatty Acids, Eicosanoids, and Intestinal Tumorigenesis. <i>Chemical and Functional Properties of Food Components Series</i> , 2005, , .	0.1	0
26	Dietary (n-6) PUFA and Intestinal Tumorigenesis. <i>Journal of Nutrition</i> , 2004, 134, 3421S-3426S.	2.9	74
27	Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. <i>Carcinogenesis</i> , 2004, 25, 2425-2432.	2.8	159
28	Transformation of Non-Cancerous Human Breast Epithelial Cell Line MCF10A by the Tobacco-Specific Carcinogen NNK. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 95-105.	2.5	36
29	Selective inhibition of Δ^6 desaturase impedes intestinal tumorigenesis. <i>Cancer Letters</i> , 2002, 175, 157-163.	7.2	37
30	Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. <i>Cancer Research</i> , 2002, 62, 403-8.	0.9	113
31	Antagonism of Arachidonic Acid Is Linked to the Antitumorigenic Effect of Dietary Eicosapentaenoic Acid in ApcMin/+ Mice. <i>Journal of Nutrition</i> , 2000, 130, 1153-1158.	2.9	75
32	Highly Unsaturated (n-3) Fatty Acids, but Not Δ^7 -Linolenic, Conjugated Linoleic or Δ^3 -Linolenic Acids, Reduce Tumorigenesis in ApcMin/+ Mice. <i>Journal of Nutrition</i> , 2000, 130, 2434-2443.	2.9	113
33	Relationship of Δ^2 -catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. <i>Carcinogenesis</i> , 1999, 20, 635-640.	2.8	89
34	Noncirrhotic portal hypertension and nodular regenerative hyperplasia of the liver in dogs with mucopolysaccharidosis type I. <i>Hepatology</i> , 1998, 28, 385-390.	7.3	26
35	Molecular Pathogenesis of Transplacentally Induced Mouse Lung Tumors. <i>Experimental Lung Research</i> , 1998, 24, 557-577.	1.2	21
36	Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I. <i>Biochemical and Molecular Medicine</i> , 1996, 58, 156-167.	1.4	157

#	ARTICLE	IF	CITATIONS
37	Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: Comparative pathology in human and nonhuman primates. , 1996, 29, 51-59.		18
38	CARCINOGENESIS: Mouse lung tumors exhibit specific Ki-ras mutations following transplacental exposure to 3-methylcholanthrene. Carcinogenesis, 1996, 17, 1519-1526.	2.8	31